96 related articles for article (PubMed ID: 18427816)
1. Copy number alterations of the polycomb gene BMI1 in gliomas.
Häyry V; Tanner M; Blom T; Tynninen O; Roselli A; Ollikainen M; Sariola H; Wartiovaara K; Nupponen NN
Acta Neuropathol; 2008 Jul; 116(1):97-102. PubMed ID: 18427816
[TBL] [Abstract][Full Text] [Related]
2. Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours.
Häyry V; Tynninen O; Haapasalo HK; Wölfer J; Paulus W; Hasselblatt M; Sariola H; Paetau A; Sarna S; Niemelä M; Wartiovaara K; Nupponen NN
Neuropathol Appl Neurobiol; 2008 Oct; 34(5):555-63. PubMed ID: 18346113
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of BMI1 confers clonal cells resistance to apoptosis and contributes to adverse prognosis in myelodysplastic syndrome.
Xu F; Yang R; Wu L; He Q; Zhang Z; Zhang Q; Yang Y; Guo J; Chang C; Li X
Cancer Lett; 2012 Apr; 317(1):33-40. PubMed ID: 22120066
[TBL] [Abstract][Full Text] [Related]
4. Nuclear-encoded cytochrome c oxidase subunit 4 regulates BMI1 expression and determines proliferative capacity of high-grade gliomas.
Oliva CR; Markert T; Gillespie GY; Griguer CE
Oncotarget; 2015 Feb; 6(6):4330-44. PubMed ID: 25726526
[TBL] [Abstract][Full Text] [Related]
5. Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients.
Wu Z; Wang Q; Wang L; Li G; Liu H; Fan F; Li Z; Li Y; Tu Y
J Neurol Sci; 2013 Dec; 335(1-2):191-6. PubMed ID: 24139839
[TBL] [Abstract][Full Text] [Related]
6. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
7. Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract.
Tateishi K; Ohta M; Kanai F; Guleng B; Tanaka Y; Asaoka Y; Tada M; Seto M; Jazag A; Lianjie L; Okamoto M; Isayama H; Tada M; Yoshida H; Kawabe T; Omata M
Clin Cancer Res; 2006 Dec; 12(23):6960-6. PubMed ID: 17145814
[TBL] [Abstract][Full Text] [Related]
8. Single-copy gain of chromosome 1q is a negative prognostic marker in pediatric nonependymal, nonpilocytic gliomas.
Miwa T; Hirose Y; Sasaki H; Ezaki T; Yoshida K; Kawase T
Neurosurgery; 2011 Jan; 68(1):206-12. PubMed ID: 21099717
[TBL] [Abstract][Full Text] [Related]
9. Bmi1 regulates cell fate via tumor suppressor WWOX repression in small-cell lung cancer cells.
Kimura M; Takenobu H; Akita N; Nakazawa A; Ochiai H; Shimozato O; Fujimura Y; Koseki H; Yoshino I; Kimura H; Nakagawara A; Kamijo T
Cancer Sci; 2011 May; 102(5):983-90. PubMed ID: 21276135
[TBL] [Abstract][Full Text] [Related]
10. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma.
Bruggeman SW; Hulsman D; Tanger E; Buckle T; Blom M; Zevenhoven J; van Tellingen O; van Lohuizen M
Cancer Cell; 2007 Oct; 12(4):328-41. PubMed ID: 17936558
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma.
Cenci T; Martini M; Montano N; D'Alessandris QG; Falchetti ML; Annibali D; Savino M; Bianchi F; Pierconti F; Nasi S; Pallini R; Larocca LM
Am J Clin Pathol; 2012 Sep; 138(3):390-6. PubMed ID: 22912356
[TBL] [Abstract][Full Text] [Related]
12. Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL.
van Galen JC; Muris JJ; Oudejans JJ; Vos W; Giroth CP; Ossenkoppele GJ; Otte AP; Raaphorst FM; Meijer CJ
J Clin Pathol; 2007 Feb; 60(2):167-72. PubMed ID: 16837630
[TBL] [Abstract][Full Text] [Related]
13. Expression of the Polycomb-Group protein BMI1 and correlation with p16 in astrocytomas an immunohistochemical study on 80 cases.
Tirabosco R; De Maglio G; Skrap M; Falconieri G; Pizzolitto S
Pathol Res Pract; 2008; 204(9):625-31. PubMed ID: 18450386
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of survivin by Bmi1 is cell type specific during corticogenesis and in gliomas.
Acquati S; Greco A; Licastro D; Bhagat H; Ceric D; Rossini Z; Grieve J; Shaked-Rabi M; Henriquez NV; Brandner S; Stupka E; Marino S
Stem Cells; 2013 Jan; 31(1):190-202. PubMed ID: 23132836
[TBL] [Abstract][Full Text] [Related]
15. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma.
Chiba T; Miyagi S; Saraya A; Aoki R; Seki A; Morita Y; Yonemitsu Y; Yokosuka O; Taniguchi H; Nakauchi H; Iwama A
Cancer Res; 2008 Oct; 68(19):7742-9. PubMed ID: 18829528
[TBL] [Abstract][Full Text] [Related]
16. Bmi1 in development and tumorigenesis of the central nervous system.
Shakhova O; Leung C; Marino S
J Mol Med (Berl); 2005 Aug; 83(8):596-600. PubMed ID: 15976916
[TBL] [Abstract][Full Text] [Related]
17. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas.
Beà S; Tort F; Pinyol M; Puig X; Hernández L; Hernández S; Fernandez PL; van Lohuizen M; Colomer D; Campo E
Cancer Res; 2001 Mar; 61(6):2409-12. PubMed ID: 11289106
[TBL] [Abstract][Full Text] [Related]
18. Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer.
Song W; Tao K; Li H; Jin C; Song Z; Li J; Shi H; Li X; Dang Z; Dou K
Cancer Sci; 2010 Jul; 101(7):1754-60. PubMed ID: 20426791
[TBL] [Abstract][Full Text] [Related]
19. CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma.
Sibin MK; Bhat DI; Narasingarao KV; Lavanya Ch; Chetan GK
Tumour Biol; 2015 Sep; 36(10):7607-14. PubMed ID: 25921285
[TBL] [Abstract][Full Text] [Related]
20. Bmi1 cooperates with Dnmt1-associated protein 1 in gene silencing.
Negishi M; Saraya A; Miyagi S; Nagao K; Inagaki Y; Nishikawa M; Tajima S; Koseki H; Tsuda H; Takasaki Y; Nakauchi H; Iwama A
Biochem Biophys Res Commun; 2007 Feb; 353(4):992-8. PubMed ID: 17214966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
